Clinical Trial Update: Open Label Extension to Assess the Safety of Long-Term Treatment With Ampion for Severe Osteoarthritis (OA) of the Knee [Phase 3]

View source ↗

Summary

Open-label extension study assessing long-term safety of Ampion in severe knee osteoarthritis; terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis of the Knee

Drugs mentioned

• Ampion

Snippet

Sponsor: Ampio Pharmaceuticals. Inc. | Conditions: Severe Osteoarthritis of the Knee | Phase 3 | Status: TERMINATED | Results posted: 2022-10-03